Prescribing information

 

   

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.

See the Cosentyx dosing schedule and summary of product characteristics.

PsO dosing: give your Cosentyx patients the ease of a monthly maintenance schedule1

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

The recommended dose for PsO is 300 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing.1

Dosing table. The recommended dose for psoriasis is 300 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing.

 

Supporting your Cosentyx patients virtually

We have now digitised our patient packs, leaflets, dosing charts and more. Make sure you can continue to support your Cosentyx patients virtually by exploring our patient resources.

Show more

 

 

More product information

Summary of product characteristics for Cosentyx

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; PsO, plaque psoriasis; SC, subcutaneous.

Reference

  1. Cosentyx Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | April 2021 | 117205
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]